{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:14:46Z","timestamp":1791918886873,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.lrr.2023.100373","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T12:11:14Z","timestamp":1685103074000},"page":"100373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Chronic-phase chronic myeloid leukemia: Incidence of BCR\/ABL transcript and its correlation with presenting features, response to treatment, and survival"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-8846","authenticated-orcid":false,"given":"Baraa","family":"Laabidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Ouahchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Boufrikha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Adnene","family":"Laatiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lrr.2023.100373_bib0001","first-page":"129","article-title":"Treatment and molecular monitoring update in chronic myeloid leukemia management","volume":"75","author":"Sorel","year":"2017","journal-title":"Ann. Biol. Clin. (Paris)"},{"issue":"1","key":"10.1016\/j.lrr.2023.100373_bib0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12032-012-0348-z","article-title":"Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia","volume":"30","author":"Bennour","year":"2013","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"issue":"1","key":"10.1016\/j.lrr.2023.100373_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12291-018-0779-1","article-title":"A prognostic and predictive study of BCR-ABL expression based on characterization of fusion transcripts","volume":"35","author":"Upadhyay","year":"2020","journal-title":"Indian J. Clin. Biochem. IJCB"},{"issue":"2","key":"10.1016\/j.lrr.2023.100373_bib0004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nprot.2006.83","article-title":"The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on","volume":"1","author":"Chomczynski","year":"2006","journal-title":"Nat. Protoc."},{"issue":"22","key":"10.1016\/j.lrr.2023.100373_bib0005","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.lrr.2023.100373_bib0006","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2023.100373_bib0007","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2023.100373_bib0008","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jcp.54.6.491","article-title":"On behlaf of the Northern Region Haematology Group. Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia","volume":"54","author":"Thomas","year":"2001","journal-title":"J. Clin. Pathol."},{"issue":"10","key":"10.1016\/j.lrr.2023.100373_bib0009","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.lrr.2023.100373_bib0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.lrr.2023.100373_bib0011","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2023.100373_bib0012","first-page":"511","article-title":"Cytogenetics in the management of \u2018chronic myeloid leukemia\u2019: an update by the Groupe francophone de cytog\u00e9n\u00e9tique h\u00e9matologique (GFCH)","volume":"74","author":"Roche-Lestienne","year":"2016","journal-title":"Ann. Biol. Clin. (Paris)"},{"issue":"12","key":"10.1016\/j.lrr.2023.100373_bib0013","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.lrr.2023.100373_bib0014","first-page":"78","article-title":"The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island","volume":"73","author":"Kuan","year":"2018","journal-title":"Med. J. Malaysia"},{"issue":"6","key":"10.1016\/j.lrr.2023.100373_bib0015","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lrr.2023.100373_bib0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2257.2002.00413.x","article-title":"BCR\/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)","volume":"24","author":"Arana-Trejo","year":"2002","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.lrr.2023.100373_bib0017","first-page":"221","article-title":"[Types of bcr-abl and their correlations with the blood count in chronic myeloid leukemia (CML) in Togo]","volume":"30","author":"Padaro","year":"2018","journal-title":"Pan. Afr. Med. J."},{"issue":"14","key":"10.1016\/j.lrr.2023.100373_bib0018","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/jcm10143146","article-title":"Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with Imatinib","volume":"10","author":"Marc\u00e9","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lrr.2023.100373_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106512","article-title":"The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"101","author":"Ghalesardi","year":"2021","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.lrr.2023.100373_bib0020","first-page":"666","article-title":"Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis","volume":"87","author":"Martinez-Mancilla","year":"2002","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.lrr.2023.100373_bib0021","first-page":"1479","article-title":"Prognostic implication of BCR-ABL fusion transcript variants in chronic myeloid leukemia (CML) treated with imatinib. A first of its kind study on CML patients of Kashmir","volume":"19","author":"Azad","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"3","key":"10.1016\/j.lrr.2023.100373_bib0022","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.lrr.2023.100373_bib0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0971-5851.133707","article-title":"Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: their correlation with presenting features, risk scores and response to treatment with imatinib mesylate","volume":"35","author":"Deb","year":"2014","journal-title":"Indian J. Med. Paediatr. Oncol. Off J. Indian Soc. Med. Paediatr. Oncol."},{"issue":"10","key":"10.1016\/j.lrr.2023.100373_bib0024","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lrr.2023.100373_bib0025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.lrr.2023.100373_bib0026","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"D'Adda","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lrr.2023.100373_bib0027","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic significance of transcript-type BCR - ABL1 in chronic myeloid leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"8","key":"10.1016\/j.lrr.2023.100373_bib0028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.lrr.2023.100373_bib0029","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:38Z","timestamp":1761959318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048923000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":29,"alternative-id":["S2213048923000134"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100373","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic-phase chronic myeloid leukemia: Incidence of BCR\/ABL transcript and its correlation with presenting features, response to treatment, and survival","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100373"}}